Show simple item record

dc.contributor.authorPavlidis, Nicholasen
dc.contributor.authorNikolaides, C.en
dc.contributor.authorBairaktari, Eleni Then
dc.contributor.authorKalef-Ezra, J. A.en
dc.contributor.authorAthanasiades, A.en
dc.contributor.authorSeferiadis, C.en
dc.contributor.authorFountzilas, Georgeen
dc.creatorPavlidis, Nicholasen
dc.creatorNikolaides, C.en
dc.creatorBairaktari, Eleni Then
dc.creatorKalef-Ezra, J. A.en
dc.creatorAthanasiades, A.en
dc.creatorSeferiadis, C.en
dc.creatorFountzilas, Georgeen
dc.date.accessioned2018-06-22T09:54:21Z
dc.date.available2018-06-22T09:54:21Z
dc.date.issued1996
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/42319
dc.description.abstractThe levels of soluble interleukin-2 receptors (sIL-2R) were measured in the serum of 52 patients with advanced colorectal carcinoma and compared to CEA and CA 19-9 levels. Twenty-five normal, age and sex-matched individuals served as controls. Seventy-five percent of the patients had increased mean serum levels of sIL-2R (1539 ± 155 U/ml), while normal controls had mean levels of 555 ± 31 U/ml (p < 0.001). The relationship with hepatic or lymph nodal metastases showed no statistically significant difference (p = 0.34 and p = 0.47, respectively). Serum sIL-2R levels showed a linear correlation with CEA (p < 0.05). Patients with lower pretreatment sIL-2R levels (less than 1.200 U/ml) had a longer survival than patients with higher initial levels (more than 1.200 U/ml) (p = 0.0049). In conclusion, the present work shows that the serum levels of sIL-2R: a) are elevated in patients with advanced colorectal cancer, b) have no relationship with the type of metastases, c) correlate with serum CEA and d) have a prognostic value for survival.en
dc.language.isoengen
dc.sourceInternational Journal of Biological Markersen
dc.subjectAge factorsen
dc.subjectArticleen
dc.subjectHumanen
dc.subjectHumansen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectControlled studyen
dc.subjectFemaleen
dc.subjectMajor clinical studyen
dc.subjectMiddle ageden
dc.subjectAdvanced canceren
dc.subjectCancer survivalen
dc.subjectPredictive value of testsen
dc.subjectPrognosisen
dc.subjectSurvival analysisen
dc.subjectTime factorsen
dc.subjectNeoplasm metastasisen
dc.subjectMaleen
dc.subjectInterleukin-2en
dc.subjectLymphatic metastasisen
dc.subjectReceptorsen
dc.subjectColorectal canceren
dc.subjectColorectal carcinomaen
dc.subjectColorectal neoplasmsen
dc.subjectLymph node metastasisen
dc.subjectSurvival timeen
dc.subjectInterleukin 2 receptoren
dc.subjectLiver metastasisen
dc.subjectBiologicalen
dc.subjectTumor markersen
dc.subjectTumor markeren
dc.subjectCarcinoembryonic antigenen
dc.subjectTumor markersen
dc.subjectSex factorsen
dc.subjectBlood levelen
dc.subjectReference valuesen
dc.subjectCa 19-9 antigenen
dc.subjectSoluble interleukin-2 receptorsen
dc.subjectCa 19-9en
dc.subjectCa-19-9 antigenen
dc.subjectCeaen
dc.titleSoluble interleukin-2 receptors in patients with advanced colorectal carcinomaen
dc.typeinfo:eu-repo/semantics/article
dc.description.volume11
dc.description.issue1
dc.description.startingpage6
dc.description.endingpage11
dc.author.facultyΙατρική Σχολή / Medical School
dc.author.departmentΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.gnosis.orcid0000-0002-2195-9961


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record